Publication Name	World Journal of Hepatology
Manuscript ID	23052
Country	Japan

Received	2015-10-16 08:17
Peer-Review Started	2015-10-16 15:11
To Make the First Decision	2015-11-24 14:58
Return for Revision	2015-11-25 08:49
Revised	2015-11-27 15:26
Second Decision	2015-12-29 11:31
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-01-07 17:05
Articles in Press	2016-01-07 17:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-11 13:39
Publish the Manuscript Online	2016-01-21 09:23

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Sofosbuvir treatment and hepatitis C virus infection
Manuscript Source	Invited Manuscript
All Author List	Masato Nakamura, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Shin Yasui, Makoto Arai, Fumio Imazeki and Osamu Yokosuka
Funding Agency and Grant Number
Corresponding Author	Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words	Hepatitis C virus; Interferon; Interferon-free; Genotype; Sofosbuvir
Core Tip	Sofosbuvir, a nucleotide-based NS5B inhibitor, is an effective treatment against pangenotypic strains of hepatitis C virus (HCV). Sofosbuvir-containing regimens have attained extremely high rates of sustained virologic response. Because regimens including sofosbuvir result in fewer adverse events than interferon-based regimens, sofosbuvir has taken a central role in HCV treatment.
Publish Date	2016-01-21 09:23
Citation	Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190
URL	http://www.wjgnet.com/1948-5182/full/v8/i3/183.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i3.183

Full Article (PDF)	WJH-8-183.pdf
Full Article (Word)	WJH-8-183.doc
Manuscript File	23052-Review.docx
Answering Reviewers	23052-Answering reviewers.pdf
Audio Core Tip	23052-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	23052-Conflict-of-interest statement.pdf
Copyright License Agreement	23052-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	23052-Language certificate.pdf
Peer-review Report	23052-Peer-review(s).pdf
Scientific Misconduct Check	23052-Scientific misconduct check.pdf
Scientific Editor Work List	23052-Scientific editor work list.pdf